XOMA. Bull or Bear? Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear?

XOMA 25.66

+2.8%

Jan 30 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Bluegreen who wrote (11251)	8/16/1999 10:06:00 PM
From: aknahow	Read Replies (1) of 17367

"Meeting with FDA to review Phase III meningococcemia trial data" This is how the release begins. Later we learn they are scheduling a meeting and we were told in the conference call that we could expect to hear something in October. It was also mentioned that the the FDA needs 4 weeks to review the data submitted. You are correct as have been other posters. XOMA has said they believe BPI was clinically effective in both mortality and morbidity. This is something raw mortality numbers would not have told us. Obviously fewer subjects receiving BPI died than in the placebo trial, and obviously fewer subjects suffered morbidity. enough fewer for XOMA to say it believed it was clinically effective. Expect we will have a meeting very soon with the FDA and of course I will be hoping the FDA does not need the full four weeks to review the data. We owe a vote of thanks to XOMA for including us in the conference call. It was probably also a wise decision to hold the call after the market had closed. I for one, needed more time and input from others to better understand the entire issue. So thanks to several other thoughtful posters on R.B., here and on Yahoo also.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next